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Abstract
Melanoma is one of the most aggressive forms of cancer and is prone to metastasis.
Once melanoma metastasizes, it is difficult to treat as patients often become immune to MAPK
inhibitors and other therapeutic agents. Small molecules, such as immune checkpoint inhibitors,
have demonstrated success as an adjunct to melanoma treatment. As a small, 18kDa molecule
with tumor suppressing properties, research using ICER continues to provide positive anti-tumor
effects. ICER regulates cAMP-induced transcription as a powerful, dominant-negative
transcriptional repressor. Recent research demonstrated that the fusion tag hemagglutinin (HA),
when fused to ICER’s N-terminus, increased ICER’s half-life and apoptotic activity in SK-MEL24 cells. If a stable, inducible HAN-ICER cell line is established, much more research will be
able to take place to further understand the role of ICER in melanoma cells. Until now, a stable
HAN-ICER cell line has not been developed despite many efforts to accomplish this in the
laboratory. Here, it was demonstrated that co-transfection with a homologous recombination
(HR) plasmid and a Cas9 gRNA plasmid which targets the AAVS1 safe harbor locus were used
to incorporate EGFP into the genome of SK-MEL-24 cells as a proof of concept. Results were
confirmed by fluorescent microscopy and Sanger sequencing data. Additionally, HAN-ICER was
integrated into the SK-MEL-24 cellular genome, and results were confirmed by western blot and
immunocytochemistry (ICC).
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Introduction
The inducible cyclic-AMP early repressor (ICER) protein is a dominant negative
transcriptional repressor and isoform of the CREM gene, and it responds to intracellular
concentrations of cAMP by downregulating cAMP-induced transcription (Molina et al., 1993,
Stehle et al., 1993). ICER has been shown to suppress cancerous cell growth in vitro as well as
suppress tumor growth in vivo (Lamas et al., 1997; Razavi et al., 1998; Yehia et al., 2001).
ICER weighs roughly 18kDa and has a simple leucine zipper structure (Poulkes et al., 1991;
Ruchaud et al., 1997). The tumor-suppressing properties and its small size make ICER an
attractive target for small molecule therapy.
It was previously demonstrated that ICER blocks DNA synthesis and cell cycle
progression in the G2/M phases in AtT20 murine pituitary corticotroph cell lines and JEG-3
human choriocarcinoma cell lines (Lamas et al., 1997; Razavi et al., 1998). In the same studies,
Lamas et al. (1997) and Razavi et al. (1998) demonstrated that exogenous expression of ICER in
AtT20 cells repress cyclin A, a tightly regulated gene product expressed at the S and G2/M
phases of the cell cycle. Another study found that ICER is the mechanism by which cAMPinduced apoptosis occurs in rat myeloid leukemia IPC-81 cells; the same study also mentioned it
may inhibit cAMP-induced apoptosis, depending on nuclear ICER concentrations and when the
apoptotic signal is initiated (Ruchaud et al., 1997). Apoptosis is a normal cellular response to
tumorigenicity (Yonish-Rouach et al., 1991). If ICER is downregulated in the nucleus,
disruption of cAMP -induced apoptosis will lead to tumor growth. ICER downregulation was
observed in the LNCaP and DU 145 human prostate cancer cell lines; untreated cells barely
express ICER, and they rapidly grow compared to cells either treated with cAMP or transfected
with ICER (Yehia et al., 2001). Yehia et al. (2001) revealed that nude mice grafted with ICER-
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expressing LNCaP cells either do not grow tumors or grow smaller tumors compared to nude
mice grafted with only LNCaP cells.
Additional research indicates that cAMP stabilizes ICER expression in JEG-3 and AtT20
cells through inhibition of the MAPK Erk1 protein kinase, which phosphorylates ICER at serine
41 and targets it for ubiquitination (Yehia et al., 2001). Site-directed mutagenesis of serine 41 to
alanine 41 results in the increased half-life of ICER. Furthermore, CDk1 phosphorylates ICER
on Ser 35 and Ser 41 during mitosis in prostate cancer cells, which leads to ICER ubiquitination.
ICER monoubiquitination results in its transportation out of the nucleus, where it is rendered
functionally inactive. Yehia et al. (2001) also found that ICER is polyubiquitinated at internal
lysine residues, which is a signal for proteasomal degradation. Site-directed mutagenesis of 11
internal lysine residues to arginine increases ICER expression, as lysine is a substrate for an E3
ligase ubiquitination reaction (Hershko & Ciechanover, 1998). The data suggest that ICER’s
half-life and nuclear concentrations are important in regulating cAMP-mediated apoptosis in
oncogenic cells, and that ICER phosphorylation and ubiquitination disrupt its ability to inhibit
tumor growth. It would follow from these experiments that modifying exogenous ICER to
prevent its unwanted phosphorylation and ubiquitination is a top consideration for its use as a
small molecule drug in cancer treatment.
Recent experiments investigating post-translational modifications of ICER found that the
availability of ICER’s N-terminus directly affected its half-life and efficiency in repressing
cAMP-mediated transcription (Cirinelli et al., 2022). This study tracked ICER’s half-life using a
hemagglutinin (HA) fusion tag on either its N-terminus or C-terminus. It was found that the
blocked N-terminus increases ICER’s half-life and transcriptional repression activity. Cirinelli et
al. (2022) also demonstrated that the HAN-ICER increases apoptotic activity as measured by
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TUNEL assays in metastatic melanoma SK-MEL-24 cell lines. Increasing the apoptotic activity
of a tumorigenic cell is a decisive goal in cancer research, and further studies are needed to
elucidate ICER’s role in apoptosis. Additionally, protein interactions involved in the
ubiquitination of ICER were identified. The promising data found in SK-MEL-24 cells, where
endogenous ICER expression is either minimal or absent, support further studies into its role in
melanoma.
Melanoma is an aggressive form of skin cancer commonly caused by a BRAF V600E
mutation (Davies et al., 2022). BRAF is a RAF isoform encoded by the BRAF oncogene which
phosphorylates MEK1 and MEK2 as part of the MAPK pathway (Marais & Marshall, 1996).
The BRAF V600E mutation leads to a constitutively active BRAF protein, which ultimately
results in the loss of cell cycle regulation and cancer. Importantly, high intracellular levels of
cAMP downregulate the MAPK pathway by interrupting the interactions between Raf and Ras
proteins (Wu et al., 1993). Inhibiting the MAPK pathway prevents cell proliferation. However,
cAMP’s impact on the MAPK pathway may be cell-specific: for example, in PC12 neuronal
cells, cAMP activates ERK1, ERK2 and Elk1 in Ras-independent pathways, leading to cell
differentiation (Vossler et al., 1997). Additionally, CDKN2A mutations may also be found in
melanoma. CDKN2A is responsible for the production of p16 and p14 proteins. In healthy cells,
p14 prevents p53 degradation and p16 binds to cyclin proteins CDK4 and CDK6, which prevents
progression through the cell cycle and thus regulates mitosis (Li, Poi, & Tsai, 2011). The
combination of BRAF and CDK2NA mutations are common in metastatic melanoma.
In 2022, the American Cancer Society (ACS) predicts that in the US, nearly 99,780 new
cases of melanoma will be diagnosed and 7,650 will die from it (ACS, 2022). Advanced
melanoma is characteristically resistant to chemotherapy, as patients either have or develop
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resistance to MAPK and BRAF inhibitors during treatment. Patients often require different
cocktails of immunotherapeutic and chemotherapeutic drugs, since multiple mutational or nonmutational events may also occur downstream of activating extracellular signals which render a
single drug ineffective (Helmbach et al, 2001; Winder & Virós, 2018; Tripathi et al., 2020).
There are numerous avenues of research which concentrate on immune checkpoint inhibitors, but
there is a gap in the literature pertaining to how transcription factors in the cAMP signaling
pathway can be studied in melanoma research (Chacon et al., 2021). Healey, Crow and Molina
(2013) found that ICER inhibits the growth of Ras-mediated melanoma R545 cells on soft agar,
and ICER also prevents melanoma genesis in SCID mice grafted with ICER-expressing R545
cells. However, R545 cells were from a murine cell line, and a better model representative for
melanoma in humans would incorporate human melanoma cell lines. In order to accomplish
this, a stably transfected human SK-MEL-24 melanoma cell line was generated.
Transfection introduces exogenous genetic material without a viral vector to a cell. Since
DNA has a negatively charged phosphate backbone, it is not readily taken up by the cell’s
negatively charged plasma membrane. The DNA must be encapsulated in a hydrophobic vessel,
cationic delivery system, or combination thereof which enables the DNA to pass into the
cytoplasm (Kim & Eberwine, 2010). Stable transfections offer the advantage of conferring
genetic integration of a gene of interest (GOI) to a host cell, thereby ensuring parental cells will
pass on the GOI to daughter cells. In order to confirm the cell successfully integrated the DNA
into its genome, reporter genes such as EGFP and drug selection markers like puromycin
resistance are incorporated into the plasmid. Cells that have integrated the GOI will fluoresce
and have resistance to puromycin, whereas cells that did not integrate the GOI will not fluoresce
and will be killed by the puromycin. In this thesis, an EGFP control was used in a plasmid of its
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own, while the protein hemagglutinin (HA) tag was fused to the N-terminus of ICER in another
plasmid. Puromycin selection was performed on both the EGFP and HAN-ICER plasmids.
Additional methods have been developed to increase transfection efficiency in the lab.
Cas9 has been used in co-transfection experiments with great efficiency to integrate a GOI into a
precise location within a genome (Liang et al., 2015). Cas9 is a CRISPR-associated
endonuclease made up of a sequence recognition domain and a nuclease domain, and it is found
in a Type II CRISPR/Cas system (Nishimasu et al., 2014). In general, a CRISPR/Cas system is
composed of palindromic repeats of 20 to 50 nucleotides divided by short spacer sequences,
downstream from a leader sequence, in a locus adjacent to cas genes. The repeats are highly
conserved but may differ depending on the CRISPR loci (Kunin, Sorek, & Hugenholtz, 2007).
The short spacer sequences are similar to sequences found in viral genomes, and it was
discovered that bacteria and archaea use CRISPR/Cas to cleave invading genetic material,
termed protospacers. Then CRISPR/Cas integrates protospacers into the spacer sequences and
the cell develops immunity to the invading virus (Barrangou et al., 2007; Bolotin et al., 2005;
Brouns et al., 2008; Jinek et al., 2012; Wiedenheft et al., 2012). The recognition of 5’ or 3’flanking protospacer adjacent motifs (PAMs) is essential to this process (Bolotin et al., 2007).
Upon bacteriophage invasion in a Type II CRISPR/Cas system, the CRISPR locus is transcribed.
Non-coding short trans-activating CRISPR RNAs (tracrRNAs) base-pair with the elongated precrRNA, form complexes with Cas9, the complexes are cleaved by RNase III, and mature
complexes ready to cleave invasive DNA are released (Bolotin et al, 2005; Brouns et al., 2008;
Deltcheva et al., 2011; Jinek et al., 2012; Lino et al., 2018; Wiedenheft et al., 2012). The crRNA
sequence is homologous to one strand of the phage DNA while the tracrRNA binds to the second
strand, and Cas9 forms double-strand breaks near the PAM sequences using RuvC- and HNH-
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like nuclease domains (Deltcheva et al., 2011; Gasiunas et al., 2012; Lino et al., 2018;
Sapranauskas et al., 2011) (Figure 1).
The understanding of CRISPR/Cas has led to revolutionary developments in the
laboratory, as gene-editing using engineered CRISPR/Cas systems is effective and easier to use
than previous methods (Javed et al., 2018; Lino et al., 2018). Based on the tracrRNA and crRNA
requirements for Cas9-mediated DNA cleavage, synthetic guide RNA (gRNA) compatible with
Cas9 was developed and it was demonstrated that the Cas9/gRNA combination successfully
targeted the GFP region within a plasmid (Jinek et al., 2012).

Figure 1. Mechanism of CRISPR/Cas9 transcription, processing, complex formation and
DNA targeting (Lino et al., 2018).

Cas9 and synthetic gRNA enable accurate targeting of specific genetic loci in host
genomes as well as plasmids to increase the efficiency of gene-editing and transfection
experiments. However, random integration or off-target effects may occur during transfection,
and researchers must use discretion when identifying the target gene locus. The AAVS1 safe
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harbor locus describes a region on chromosome 19 in the human genome where the adenoassociated virus (AAV) inserts its DNA (Kotin, Linden, & Berns, 1992). AAVS1 is termed a
safe harbor because modifications in this area of the genome do not result in observable cellular
changes or disruptions to essential cellular systems. DNA in this locus may therefore be targeted
with Cas9 gRNA and repaired via homologous recombination (HR), where an HR plasmid
containing the desired transgene will safely integrate into the host genome.
Until today, a stable inducible ICER cell line was unable to be produced in SK-MEL-24
cells for reasons that are currently not clear. It is thought that a disruption in cell signaling or
exogenous gene silencing takes place soon after transfection which causes the cells to undergo
apoptosis. Here, a stable inducible EGFP-only cell line was generated in SK-MEL-24 cells
(referred to as SK-MEL-EGFP) via co-transfection, as proof of concept using a Cas9 gRNA
plasmid and a tetracycline-inducible HR plasmid. The plasmids were then used to stably
transfect SK-MEL-24 cells with HAN-wildtype ICER (SK-MEL-459). My hypothesis is that
gene integration occurs in the AAVS1 safe harbor locus via homologous recombination of the
donor plasmid, and HAN-ICER is expressed when the cells are exposed to doxycycline.

14
Materials and Methods
Cells, Cell Culture, and Transfection
SK-MEL-24 human melanoma cells were purchased from ATCC® and cultured with
Eagle’s Minimum Essential Medium (EMEM),15% heat-inactivated Fetal Bovine Serum (HIFBS) and Pen Strep (5.0mL P/S per 500.0mL EMEM) in a 75 cm2 culture flask until 80%
confluency. To split the cells, media was aspirated, and flask was rinsed with 5.0mL phosphate
buffered saline (PBS). Trypsin (2.0mL 0.25%) was added to the flask which was then placed in
a 37.0°C incubator for 5 minutes. EMEM/15% Tet-free FBS plus P/S (18.0mL) was added to the
culture flask after incubation. 900.0uL aliquots were dispensed evenly in a 6-well 10mm2 plate.
Cells were transferred to a 37.0°C incubator and incubated for 24 hours, until 80% confluency.
Cells were then removed from the incubator and media was replaced with 2.0mL EMEM plus
Tet-free 15% FBS. Cells were transfected using the Promega Fugene® HD Transfection
Reagent. Tet-free 15%FBS/EMEM (72.0µL), 8.0µL Fugene® HD, 10.0µL (0.1µg/µL) Teton®3G-HAN-zfICERwt-AAVS1-HR plasmid, and 10.0µL (0.1µg/µL) All-in-One Cas9
SmartNuclease™ EF1-hspCas9-H1-AAVS1-gRNA plasmid (System Biosciences) were added to
Eppendorf tubes (plasmid maps can be seen in Figure 2 and Figure 3). The EGFP control group
was transfected as described with the Tet-on®3G-EGFP-AAVS1-HR (figure not shown) and
EF1-hspCas9-H1-AAVS1-gRNA plasmids. Eppendorf tubes sat at room temperature for 15
minutes and transfection solution was pipetted equally into each well. Cells were incubated at
37.0°C overnight. Media was aspirated and replaced with 2.0mL EMEM/P/S and 15% Tet-free
FBS.
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Figure 2. Snapgene® plasmid map depicting HAN-ICER under the TRE3G promoter. The Teton® 3G protein changes its conformation after binding with doxycycline and then binds the
TRE3G promoter to induce transcription.
Puromycin Selection
Cells were recovered approximately 10 days post-transfection. Puromycin (10.0mg/mL) was
diluted 1:10 with deionized water (dH2O) and then added to 10.0mL EMEM/15% Tet-free FBS,
for a final concentration of 0.5µg/mL puromycin. Cells were removed from the incubator, media
was aspirated and replaced with 2.0mL of the freshly made puromycin-containing media, and
then incubated at 37°C for three days. Media was replaced every three days. Puromycin-resistant
colonies developed after two weeks and were transferred to separate wells and allowed to grow
for two passages before being split as described.
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Figure 3. Snapgene® plasmid map depicting the Cas9 gRNA which targets and cleaves the
AAVS1 locus.

Doxycycline Addition and Western Blot Analysis
Doxycycline [20.0µL (0.5µg/mL)] was added to wells containing SK-MEL-459B, SK-MEL459C, and SK-MEL-EGFP5 (letters or numbers following the name of a cell line distinguish the
identity of a selected colony). Water was added to separate wells of these cell lines as a negative
control, and cells were incubated for 48 hours to achieve maximum induction. After the
incubation period, cells were observed for fluorescence using the Nikon® Eclipse Ti inverted
fluorescent microscope. Media was aspirated and cells were rinsed with PBS, then 500.0µL
trypsin was added to each well. After cells incubated for three minutes, 1.0mL EMEM/15% HIFBS +P/S was added to inactivate trypsin, cells were aliquoted into 1.5mL Eppendorf tubes and
then centrifuged at 300g for 6 minutes. Samples for SDS-PAGE and Western Blot were prepared
and performed as previously described (Yehia et al., 2001). Western blot detection was
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performed using the LI-COR Odyssey CLx®. Rabbit monoclonal anti-HA antibodies were used
as primary antibodies and were purchased from Invitrogen. IRDye® secondary antibodies were
purchased from LI-COR for western blot imaging.
DNA Extraction and PCR
SK-MEL-459B/C and SK-MEL-EGFP1/5 cells were removed from wells and DNA was
extracted per the Qiagen® DNeasy® Blood and Tissue Kit Quick-Start protocol. The forward
HR primer selected for plasmid amplification was 5’-CCTCTGAACGCTTCTCGCTG-3’ and
the reverse HR primer was 5’-CGTACCACTTCCTACCCTCG-3’. PCR was performed
according to DreamTaq Green PCR protocol (Thermo Scientific™).
Gel Electrophoresis and Sequencing
PCR-amplified DNA (10.0µL) was loaded into wells for 1.0% agarose gel electrophoresis. Gel
was imaged using GelRed® Nucleic Acid Gel Stain under a UV light and the PCR product was
sent to Genewiz from Azenta Life Sciences in South Plainfield, NJ for Sanger Sequencing. The
forward primer included was 5’- CCTCTGAACGCTTCTCGCTG-3’.
Immunocytochemistry (ICC)
ICC was performed with anti-HA fluorescently tagged primary antibodies (anti-HA, mouse
IgG1, clone 16B12, Alexa Fluor 594 [ThermoFisher Cat # A21288] at a dilution of 1:200). Cells
were fixed and prepared as previously described (Cirinelli et al., 2022). After 100µL of primary
antibody was applied to the samples, samples were incubated at 4°C overnight and then rinsed
with PBS. DAPI [100µL (1.2µL/mL)] was then added. Samples sat for 30 minutes at room
temperature before being rinsed with PBS and prepared for imaging with the Nikon® Eclipse Ti
inverted fluorescent microscope.
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Results
Doxycycline induced EGFP expression in SK-MEL-EGFP cells
Maximal induction of EGFP expression, as determined by the number of fluorescent cells,
occurred approximately 48 hours after treatment with doxycycline (Figure 4), demonstrating that
inducibility and plasmid integration were successful. Interestingly, the SK-MEL-EGFP1 cells
stopped fluorescing (data not shown). Increasing doxycycline did not result in fluorescence.
However, SK-MEL-EGFP5 cells continue to fluoresce.

Figure 4. Fluorescent microscopy showing images viewed of SK-MEL-EGFP cells before (left)
and after (right) addition of doxycycline (10X).

Western blot analysis demonstrated inducible HAN-ICER expression
To identify inducible HAN-ICER expression, a western blot was performed using antiHA antibodies (Figure 5). Both 459B and 459C colonies expressed HAN-ICER after doxycycline
addition as seen in the approximate 22kDa band region in lanes 2 and 4. ICER runs on a western
blot at a slightly higher molecular weight than its structural molecular weight of 18kDa, and the
fusion HA tag adds approximately 1kDa to the overall molecular weight, both of which account
for the observed molecular weight. The subdued HAN-ICER bands at 22kDa do not appear in
the negative control lanes, which demonstrate that doxycycline induced HAN-ICER expression in

19
SK-MEL-24 cells. Additionally, 20.0µL of the 459B(+) and 459C(+) HAN-ICER cell extracts
were loaded, compared to 10.0µL volumes loaded in each of the other respective lanes. This was
done as it was unknown how strong the HAN-ICER signal would be. Despite doubling the
protein volume loaded into the lanes, HAN-ICER expression appears subdued. Research into
factors influencing HAN-ICER expression in SK-MEL-24 cells is still new and more is expected
to be learned. The expression signals in lanes 8 and 9 are greater than those appearing in 2 and 4
as the lanes were overloaded, in the event no HAN-ICER bands appeared in lanes 2 and 4.
Theoretically, bands should not be visible in the EGFP lanes, as anti-EGFP antibodies
were not used in this experiment. Mass spectrometry would need to be performed in order to
identify background expression, but it is doubtful that any significant information would result
which pertains to the scope of this experiment.

Figure 5. Western blot depicting HAN-ICER expression in lanes 2, 4, 8, and 9.
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Sanger Sequencing
Sanger sequencing data confirmed successful integration of the HR donor plasmid for
EGFP5. The sequence for the extracted DNA was aligned with the HR plasmid DNA in
Snapgene® software, as seen in Figure 6. There were three mismatches, no insertions, and no
gaps in the alignment. However, these data do not confirm that the HR plasmid was integrated
in the AAVS1 safe harbor locus, as primers would need to be selected for the nucleotide
sequences flanking the genomic AAVS1 site. However, there was no abrupt cell death posttransfection, nor were any discernable morphological effects observed in the cells. Sequencing
primers for genomic AAVS1locus were recently identified and designed, but sequencing results
for 459B and 459C were not available by the time this thesis was completed.

Figure 6. Snapgene® sequence alignment of purified genomic EGFP with the plasmid DNA.
Purified genomic EGFP is represented by the blue arrow in the beige horizontal bar aligned
above the linear plasmid map.

ICC demonstrates stable cell lines were generated with inducible HAN-ICER
To compare stably transfected SK-MEL-459 (459B and 459C) colonies with transiently
transfected HAN-ICER colonies, 459B and 459C cell colonies were passaged for about one week
before performing ICC. SK-MEL-24 cells were then transiently transfected with a pCMV
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plasmid (SK-MEL-390). Transient transfections deliver exogenous DNA to the cell’s nucleus,
but it is not integrated into the genome; because of this, the DNA is eventually degraded, and
progeny cells do not acquire the transfected genes. On the other hand, the stably transfected cells
which were passaged were expected to demonstrate that all the cells express HAN-ICER. The
cells seen in Figure 7A were transiently transfected with HAN-ICER and Figures 7B and 7C
demonstrate 459B and 459C cells, respectively. DAPI was used as a counterstain to verify that
cells, not random artifacts, were expressing fluorescently labeled HAN-ICER. Clearly, HANICER expression in SK-MEL-390 cells is deficient compared to both 459B and 459C cell
colonies.

Figure 7A (left) and Figure 7B (right). ICC performed on cells transiently transfected with HANICER using a pCMV plasmid (10X). Transfection efficiency was calculated as the number of
fluorescent cells divided by the total number of cells counted in a random field. DAPI image on
the left is shown for reference.
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Figure 7C (left) and Figure 7D (right). 459B and 459C colonies were passaged for about one
week before ICC was performed. Stable transfections with the HR plasmid and Cas9 gRNA in
459B and 459C HAN-ICER colonies show that all cells are expressing HAN-ICER (10X). DAPI
image on the left is shown for reference.

Transfection efficiency was calculated as the number of fluorescent cells divided by the total
number of cells in the microscopic field at 10X magnification. The transfection efficiency for
the SK-MEL-390 cell colonies was about 21%. As the 459B and 459C colonies were passaged
for about one week before staining and imaging, these results confirm that stable, puromycinselected and dox-inducible HAN-ICER cell lines were created.
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Discussion
ICER expression decreases in active melanoma, as it is phosphorylated in the MAPK
pathway, polyubiquitinated, and targeted to proteasomal degradation (Healey, Crow, & Molina,
2013). ICER is also monoubiquitinated and shuffled out of the nucleus into the cytosol, where its
role as a transcriptional repressor is disabled (Mémin et al., 2011). Since endogenous baseline
ICER expression is low in healthy melanocytes, melanoma cells express almost imperceptible
levels of ICER. In experimenting with the HA tag on ICER’s N-terminus and C-terminus to
trace ICER expression in melanoma cells, it was discovered that the HA tag on the N-terminus
reduces protein turnover (Cirinelli et al., 2022). In order to study the importance of HAN-ICER
expression in melanoma, stable cell lines were needed, but the transfection complexes used prior
to these experiments resulted in rapid cell death. This thesis demonstrates that a stable cell line
expressing HAN-ICER was created, and these cells form the foundation for future HAN-ICER
experiments to follow.
Using the AAVS1 Cas9 gRNA plasmid and tet-inducible expression HR plasmid, the
results of this study demonstrated that EGFP and HAN-ICER were integrated into the genome of
SK-MEL-24 cells. Doxycycline was able to induce the expression in SK-MEL-EGFP cells, as
shown by fluorescent microscopy. It is interesting to note that after two cell passages, the SKMEL-EGFP1 colonies stopped fluorescing. Krishnan et al. (2006) documented that epigenetic
silencing of reporter genes occurred in H9c2-Fluc cells after months of cell passages, but
reporter gene expression was recovered after exposing the cells to methyltransferase and
deacetylase inhibitors, as well as a transcriptional activator. In SK-MEL-24 cells, two cell
passages equate to approximately one week. If EGFP was epigenetically silenced within one
week, methylation studies on the TRE3GS promoter should be performed in the transfected cells
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via the bisulfite conversion method. This method relies on the conversion of unmethylated
cytosine to uracil residues to confirm the degree of promoter methylation. On the other hand,
methyltransferase and deacetylase inhibitors may also be used to see if there is an impact on the
duration of EGFP expression. Epigenetic silencing would render doxycycline addition
ineffective, because the promoter would be structurally obstructed after methylation. It was
observed that doubling the amount of doxycycline to SK-MEL-EGFP cells did not cause the
cells to regain fluorescence, and promoter methylation should be considered because of this
observation. In addition, a duplicate experiment demonstrated that (data not shown)
approximately 10% of SK-MEL-EGFP cells fluoresced before they were exposed to
doxycycline, but not with the same intensity as if they were exposed to dox. This may indicate a
leaky promoter, where EGFP was transcribed despite the absence of doxycycline, which is
required to induce the conformational change in the transactivator necessary for tet operator
binding in the promoter.
Expression of HAN-ICER was observed in the Western blot, although the bands appeared
weak. This may have been the result of protein loading; α-tubulin was not used to verify the
amount of protein loaded in each lane. The relatively low intensity of the ~22kDa HAN-ICER
bands may indicate that silencing occurs to a small extent, but repeated experiments need to be
performed to identify whether the band intensity increases, and α-tubulin must be used as a
loading control. Many unidentified protein bands were also observed, although anti-HA and
IRDye® were the only antibodies used in the procedure. Western blots may often generate
images like this, and the causes may be the result of nonspecific antibody binding, secondary
antibodies forming conjugates, or general interference. Cirinelli et al. (2022) demonstrated in
their mass spectrometry data that there are many proteins which potentially interact with ICER,
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such as UBR4 and NAA15, and it is likely that other proteins interact with ICER in different
capacities. Most important in this Western blot is the presence of two 22kDa bands specific to
lanes 2 and 4, which demonstrate HAN-ICER expression. Additionally, it was concluded from
the ICC results that the SK-MEL-459B and SK-MEL-459C colonies were stably transfected with
HAN-ICER, as after about two passages demonstrate in Figures 7C that all cells fluoresce upon
exposure to anti-HA antibodies. Importantly, the cells continue to be passaged. Previous
experiments were unsuccessful in maintaining ongoing cell viability. These results and
observations support the hypothesis that HAN-ICER integrated into the AAVS1 locus.
The sequencing results confirm that the EGFP5 plasmid was integrated into the SKMEL-24 genome. Although it was unable to be verified that the HR plasmid integrated in the
AAVS1 locus (as compared to a random locus), the principle behind homologous recombination
supports the hypothesis that the HR plasmid was inserted into the AAVS1 locus. Homologous
recombination does not rely on restriction sites; rather, any extended region of DNA with enough
similarity to another long strand of DNA can initiate homologous recombination after a dsDNA
break. In this experiment, Cas9 gRNA (synthetic crRNA fused to tracrRNA) and an HR plasmid
were used. The gRNA recognizes the AAVS1 locus and forms a complex with Cas9, which then
causes a dsDNA break. The HR plasmid serves as the repair template for homologous
recombination at the AAVS1 locus, as the flanking ends of the HR plasmid are homologous to
the flanking ends of the genomic AAVS1 DNA. EGFP, located in between the flanking arms of
the HR plasmid, was then introduced into the cell’s genome. A limitation to this thesis was that
the flanking sequences of the AAVS1 locus in the genome were recently identified and primers
were designed, but sequencing has yet to be performed. Sanger sequencing will be needed to
confirm that the EGFP and HAN-ICER sequences were inserted into the target AAVS1 locus.
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Importantly, experiments with the SK-MEL-459 cell lines will shed light on the
interactions between UBR4 and ICER; UBR4 was found to ubiquitinate ICER according to the
N-end rule proteasome pathway (Cirinelli et al., 2022). Cirinelli et al. (2022) also demonstrated
that NAA15 interacts with ICER and influences its expression. Research exploring how UBR4,
NAA15 and other ubiquitin ligases affect ICER will provide further insight into the mechanisms
involved, now that HAN-ICER is integrated in the melanoma cell’s genome. The ability to
control HAN-ICER expression with dox will show how HAN-ICER affects melanoma cells,
especially regarding protein interactions in the proteasome pathway, as well as apoptosis.
It was previously established that ICER downregulates Bcl-2 expression in myocytes
(Tomita et al., 2003). Bcl-2 is an anti-apoptotic protein expressed by the BCL2 gene, which
contains a cAMP response element (CRE) where ICER can bind. If ICER is phosphorylated and
either mono- or polyubiquitinated, it may not bind the Bcl-2 promoter, which may contribute to a
sustained pro-survival signal in melanoma tumorigenesis. Since HAN-ICER is more resistant to
polyubiquitination due to the presence of the HA tag on the N terminus, experiments may be
performed in stable cell lines which will elucidate the interaction between ICER and Bcl-2.
The Bcl-2 associated agonist of cell death (Bad) protein, a proapoptotic protein part of the Bcl-2
family of proteins, is inactivated in melanoma cells by the 90kDa ribosomal S6 kinase (RSK)
phosphorylation via the MAPK pathway (Eisenmann et al., 2003). Further research would
indicate if ICER binding the BCL2 promoter impacts the pro-apoptotic interaction between Bad
and Bcl-2. It is interesting to note that DeGroot et al (2004) identified that the 70kDa RSK
phosphorylates CREM in the nucleus; the 90kDA isoform was also analyzed but results were not
conclusive at the time. However, RSK proteins clearly affect apoptosis in melanoma cells and
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interact with substrates that are involved with or influenced by ICER, and future studies may find
a tangible relationship between RSKs and ICER.
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Conclusion
This thesis documents that for the first time, a stable cell line expressing HAN-ICER was
generated using cotransfection with a tetracycline-inducible homologous recombinant AAVS1
plasmid and Cas9 gRNA which targets the AAVS1 locus. Through homologous recombination,
it was likely incorporated into the AAVS1 locus. The data were confirmed with Western blot
analysis and immunocytochemistry. However, sequencing results are needed to verify that HANICER and EGFP were integrated into the AAVS1 locus. HAN-ICER, with a decreased turnover
rate and increased nuclear localization, will elucidate how it may be used against aggressive,
metastatic melanoma in SK-MEL-24 cells. Future experiments will continue to focus on protein
interactions, apoptosis, and using HAN-ICER in drug delivery systems.
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